JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform

HYOGO, Japan--(BUSINESS WIRE)--Acumen exercised its option to develop, manufacture, & commercialize, on a global basis, up to two candidates for development in the treatment of AD.